Shane Schaffer

Shane Schaffer is the co-founder, Chairman, and CEO of Cingulate Therapeutics, based in Kansas City, Kansas. This Phase 3 clinical-stage biopharmaceutical company is dedicated to developing and managing innovative next-generation pharmaceutical products, mainly targeting Attention Deficit/Hyperactivity Disorders (ADHD), along with anxiety disorders and insomnia. A seasoned professional with 25 years in the pharmaceutical industry, he specializes in drug development and commercialization. His leadership and entrepreneurial skills have been instrumental in various business areas, including product launches, brand planning, joint venture brand management, life cycle management, and market development, establishing him as a notable figure in biopharmaceutical and marketing. He earned his doctoral degree in Pharmacy from the University of Kansas in 1999, followed by a postdoctoral pharmaceutical industry fellowship at Rutgers University's College of Pharmacy. During this fellowship, he worked at Pfizer Worldwide Marketing and Morris Plains, taking significant strides in marketing and research management. While at Pfizer Worldwide Marketing in New York, NY, he served as a Marketing Manager, developing pre-launch strategies and initiating the Global Communications Intranet to improve communications between medical and marketing stakeholders. His professional journey continued across leading pharmaceutical firms, including Pfizer, Novartis, and Sanofi, where he held multiple managerial roles and was pivotal in developing and commercializing several billion-dollar brands. At Novartis, he passionately managed the Ritalin® LA and Focalin™ segments, significantly boosting the ADHD franchise with innovative strategies that achieved remarkable market penetration shortly after launch. His efforts garnered him several prestigious awards for his strategic and operational excellence.